Drug Database
Back to search

Poland· PL-100312311

NovoRapid

A insulin aspart product containing insulinum aspartum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 11 of our 19 countries.

ATC A10AB05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNovoRapidATCA10AB05REGISTER NO.PL-100312311PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulinum aspartumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin aspart is registered in 11 of 19 countries.

Countries holding a registration under ATC A10AB05 (insulin aspart), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search insulin aspart products by name

Insulin aspart · ATC A10AB05

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Insulinum aspartum
Manufacturer
Novo Nordisk A/S
Country
Poland (PL)
ATC code
A10AB05
ATC class
Insulin aspart
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • gtin
    05909991369668
    1 fiol.po 10 ml
    PLN 81.09

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin aspart.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin aspart against other medicinesHow interaction checks work

Insulin aspart · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin aspart in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin aspart products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Dazparda, Fiasp
  • Liechtenstein · Dazparda, Insulin Aspart Sanofi
  • Norway · Dazparda, Fiasp

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cd07ec09-233f-4804-8124-21a40be5ec93
GET /v1/drugs/cd07ec09-233f-4804-8124-21a40be5ec93?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "100 j./ml",
  "packaging": "05909991369668 ¦ Rp ¦ EU/1/99/119/001 ¦ 89953\n1 fiol. 10 ml\nRp ¦ EU/1/99/119/008 ¦ 89956\n5 fiol. 10 ml\nRp ¦ EU/1/99/119/015 ¦ 89957\n5 fiol. 10 ml (5x1)",
  "substance": "Insulinum aspartum 100 j.m./1 ml",
  "common_name": "Insulinum aspartum",
  "pl_product_id": "100312311",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about insulin aspart.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console